Weipert Kay F, Bauer Timm, Nef Holger M, Möllmann Helge, Hochadel Matthias, Marco Jean, Weidinger Franz, Zeymer Uwe, Gitt Anselm K, Hamm Christian W
Department of Cardiology, Justus-Liebig University of Giessen, Giessen, Germany.
Department of Cardiology, Kerckhoff Klinik, Bad Nauheim, Germany.
Heart Vessels. 2016 Sep;31(9):1438-45. doi: 10.1007/s00380-015-0754-1. Epub 2015 Oct 5.
The clinical benefit of thrombus aspiration (TA) in patients presenting with acute ST-elevation myocardial infarction (STEMI) and treated with primary percutaneous coronary intervention (PCI) is not well defined. Furthermore, there is a large variation in the use of TA in real-world registries. Between 2005 and 2008, a total of 7146 consecutive patients with acute STEMI undergoing primary PCI were prospectively enrolled into the PCI Registry of the Euro Heart Survey Programme. For the present analysis, patients treated additionally with TA (n = 897, 12.6 %) were compared with those without TA (n = 6249, 87.4 %). Patients with hemodynamic instability at initial presentation (15.1 vs. 11.0 %; p < 0.001) and resuscitation prior to PCI (10.4 vs. 7.4 %; p = 0.002) were more frequently treated with TA. TIMI flow grade 0/1 before PCI was more often found among those with TA (73.5 vs. 58.6 %; p < 0.001). After adjustment for confounding factors in the propensity score analysis, TA was not associated with improved in-hospital survival (risk difference -1.1 %, 95 % confidence interval -2.7 to 0.6 %). In this European real-world registry, the rate of TA use was low. Hemodynamically unstable patients were more likely to be treated with TA. Consistent with the results of the TASTE study and the TOTAL trial, TA was not associated with a significant reduction in short-term mortality.
在急性ST段抬高型心肌梗死(STEMI)患者中,经皮冠状动脉介入治疗(PCI)时血栓抽吸术(TA)的临床益处尚不明确。此外,在实际临床登记中,TA的使用存在很大差异。2005年至2008年期间,共有7146例连续接受直接PCI的急性STEMI患者前瞻性纳入欧洲心脏调查项目的PCI登记研究。在本分析中,将接受TA额外治疗的患者(n = 897,12.6%)与未接受TA治疗的患者(n = 6249,87.4%)进行比较。初始表现为血流动力学不稳定的患者(15.1%对11.0%;p < 0.001)以及PCI前接受复苏的患者(10.4%对7.4%;p = 0.002)更常接受TA治疗。PCI前TIMI血流0/1级在接受TA治疗的患者中更常见(73.5%对58.6%;p < 0.001)。在倾向评分分析中对混杂因素进行校正后,TA与住院生存率改善无关(风险差异 -1.1%,95%置信区间 -2.7至0.6%)。在这个欧洲实际临床登记研究中,TA的使用率较低。血流动力学不稳定的患者更有可能接受TA治疗。与TASTE研究和TOTAL试验的结果一致,TA与短期死亡率的显著降低无关。